Alleviation of autoimmune disease in MRL-lpr mice by administration of Ye19.1, a monoclonal specific for the lpr T cell antigen, LTA.
The MRL-lpr murine model of systemic lupus erythematosus (SLE) has provided many insights into the pathology of human lupus. The model is characterized by an age-dependent expansion of a Thy-1+ alpha beta/CD3+ CD4-, CD8- T-cell subset in the nodes and spleen. In this study, a lpr T-cell specific monoclonal antibody, Ye19.1, was found to bind to a 200 kDa cell surface molecule (termed LTA) which has a phosphotyrosine phosphatase (PTPase) enzymatic function. The significance of this marker in the development of autoimmune pathology in MRL/lpr mice was also demonstrated; treatment of MRL-lpr mice with the Ye19.1 Ab was shown to retard the development of the autoimmune syndrome and to restore the T cell-dependent immune response to ovalbumin.
Gallina
M C
MC
Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California 92037.
Steele
J K
JK
D000375:Aging / Q000276:immunology; D000818:Animals; D000974:Antibodies, Antinuclear / Q000096:biosynthesis; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000917:Antibody Formation / Q000187:drug effects; D015551:Autoimmunity; D015415:Biomarkers; D015153:Blotting, Western; D005434:Flow Cytometry; D066298:In Vitro Techniques; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D051379:Mice; D008815:Mice, Inbred Strains; D017027:Protein Tyrosine Phosphatases / Q000032:analysis; D013601:T-Lymphocytes / Q000276:immunology
D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D017027:Protein Tyrosine Phosphatases